This study was conducted to assess the safety and tolerability of the alternative formulation vehicles polysorbate 80 (PS80), propylene glycol (PG), and hydroxypropyl-beta-cyclodextrin (HPbCD) in general toxicology studies in the mouse, rat, dog, and monkey. Twenty (20) mg/kg of hydroxypropyl methylcellulose (MC, control), 10 mg/kg PS80, 1000 mg/kg PG, 500 mg/kg HPbCD, or 1000 mg/kg HPbCD were administered by oral gavage to mice, rats, dogs, and cynomolgus monkeys for approximately 90 days. The effects of these formulations on clinical observations, body weight and food consumption parameters, clinical pathology, and histopathology were evaluated across all species. The suitability of formulations containing up to 20 mg/kg MC, 10 mg/kg PS80, and 1000 mg/kg PG for use in preclinical safety studies was confirmed by a lack of effects on all parameters examined. However, formulations containing HPbCD produced elevated transaminase (aspartate and alanine aminotransferase) levels in rats and mice and fecal changes (loose and soft stool) in large animals. Although the etiology and toxicological significance of the transaminase elevations in rats and mice is uncertain, this finding could represent a significant liability for a preclinical formulation because of the critical importance of these biomarkers in the risk assessment of novel therapeutic agents. Based on these data, PS80 and PG are considered to be practical alternatives to MC in preclinical toxicology studies. However, formulations containing HPbCD should be used with caution because of the elevations in rodent transaminase levels.
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The development of poorly soluble or permeable pharmaceutical therapies (Biopharmaceutics Classification System II-IV) has become increasingly common in the pharmaceutical industry. As such, there exists an increasing need for a wide variety of vehicle formulations that can enhance exposure of highly insoluble new molecular entities (NCEs) during preclinical safety and toxicokinetic studies. Although many such vehicles, such as methylcellulose, have been extensively studied and are generally believed to be without biological effects at typical doses, the toxicities of numerous vehicles with favorable solubilizing characteristics are not completely understood and warrant further investigation. Unexpected vehicle-related toxicities can be difficult to segregate from NCE-related toxicities and are therefore best avoided by detailed characterization of preclinical vehicles using appropriate test systems prior to use in safety studies.
The ideal preclinical vehicle is able to be administered via the intended clinical route, provides for suitable stability and bioavailability of the NCE, and is without biologic effects on the test system. However, the standardization of vehicle use across the industry is hindered by the varied physiochemical properties of NCEs in development and a tendency of sponsors to use vehicles with which they have previous experience. Indeed, a survey of the pharmaceutical industry reveals highly divergent vehicle use (Gad et al., 2006) . The publication of robust studies critically assessing the suitability of vehicles for use in preclincial studies may serve to eliminate duplicated efforts between sponsors, as well as unexpected vehicle-related toxicities. Such vehicle-related toxicities can prove costly as they may confound and delay the development and marketing of novel NCEs.
Work in our laboratories focused on the use of polysorbate 80 (PS80), propylene glycol (PG), and hydroxypropyl-betacyclodextrin (HPbCD) as alternative preclinical formulations. A survey of the available literature revealed an incomplete and at times out-of-date toxicity profile for these vehicles. The published literature is particularly deficient with respect to reproductive toxicity assessments, assessment of toxicity in the dog and monkey, and robust good laboratory practice (GLP)-quality studies incorporating end points such as in-depth clinical pathology, full histopathology, and safety pharmacology end points in large animals. In the present studies, we have completed a battery of oral safety studies using these vehicles and hydroxypropyl methylcellulose (MC, used as a control group). The goal of these studies was to determine their suitability for future use in Investigational New Drug (IND)-enabling preclinical safety studies. As such, the studies performed were robust GLP safety studies designed to fill in all gaps in the toxicity profile of P80, PG, and HPbCD and provide confidence that such vehicles can be used when assessing potentially life-saving NCE in future safety studies.
Presented here are the general toxicology studies (3-month mouse, rat, dog, and monkey studies), whereas a companion publication (Enright, McIntyre, Thackaberry, Treinen, and Kopytek, unpublished data) details the reproductive toxicology studies performed. The lack of genetic toxicity of these vehicles has been previously established (Crofton-Sleigh et al., 1993; Elder, 1984; Haworth et al., 1983; Hodge et al., 1950; National Toxicology Program, 1992; Waner et al., 1995) . The suitability of formulations containing up to 20 mg/kg MC, 10 mg/kg PS80, and 1000 mg/kg PG for use in preclinical safety studies was confirmed by a lack of effects on all parameters examined. However, findings in both general and reproductive toxicology studies demonstrate that oral HPbCD administration has liabilities in multiple species that may confound data interpretation and therefore should be carefully considered prior to use in preclinical safety studies. Furthermore, we demonstrate that oral HPbCD administration produces toxicities that are distinct from those produced in the same species by iv HPbCD administration. Animals and study designs. Sprague-Dawley (Crl:CD[SD]VAF/Plus) rats (10/sex/group) were obtained from Charles River Laboratories (Wilmington, MA). Rats were 6 ± 1 weeks old at initiation of dosing. Males were 220.7-295.5 g and females 150.0-201.5 g at the initiation of dosing. All rats on study were individually housed in suspended, stainless steel cages, were maintained on a 12-h light cycle (temperature 72°F ± 4°F, 30-70% humidity), and were given water and certified rodent lab diet (PMI Nutrition International, Inc.) ad libitum. Vehicles were administered orally via gavage (dose volume of 5 ml/kg, calculated from most recent body weight) for 92-93 days using an appropriately sized syringe and a ball-tipped gavage tube. Body weight was measured weekly beginning 1 week prior to dosing, and a fasted terminal body weight was recorded prior to necropsy. Food consumption was measured weekly beginning 1 week prior to dosing. Rats were checked at least once daily for viability and clinical observations were recorded twice daily, at the time of dosing, and 1-3 h postdose.
MATERIALS AND METHODS
CD1 (Crl:CD1[Icr]VAF/Plus) mice (10/sex/group) were obtained from Charles River Laboratories and were 6 ± 1 weeks old at initiation of dosing. Weight of mice at initiation of dosing was 25.4-33.6 g for males and 19.3-27.0 g for females. Mice were individually housed in suspended, stainless steel cages, maintained on a 12-h light/dark cycle (temperature 72°F ± 4°F, 30-70% humidity), and provided water and certified rodent feed (PMI) ad libitum. Vehicles were administered orally via gavage (dose volume of 10 ml/kg, calculated from most recent body weight) for 92-93 days using an appropriately sized syringe and a ball-tipped gavage tube. Body weight was measured weekly beginning 1 week prior to dosing, and a fasted terminal body weight was recorded prior to necropsy. Food consumption was measured weekly beginning 1 week prior to dosing. Mice were checked at least once daily for viability and clinical observations were recorded twice daily, at the time of dosing, and 1-3 h postdose.
Beagle dogs (4/sex/group) were obtained from Marshall Farms (North Rose, NY) and were 7-17 months old at the initiation of dosing. Males were 7.3-11.0 kg and females were 6.2-9.4 kg at initiation of dosing. Dogs were individually housed in runs, maintained on a 12-h light/dark cycle (temperature 68°F ± 4°F, humidity 30-70%), and provided Certified Canine LabDiet 5007 daily and water ad libitum. Vehicles were administered orally by gavage (dose volume of 5 ml/kg, calculated from most recent body weight) for 95-97 days using an appropriately sized syringe and catheter. Body weights were measured at least weekly beginning 3 weeks prior to dosing, and a fasted terminal body weight was recorded prior to necropsy. Food consumption was estimated daily beginning 1 week prior to dosing. Dogs were checked at least once daily for viability and clinical observations were recorded twice daily, at the time of dosing, and 1-3 h postdose.
Cynomolgus monkeys (Macaca fascicularis, 4/sex/group) were obtained from Covance Laboratories (Alice, TX) and were 2.8-4.0 kg (males) or 2.0-3.6 kg (females) at initiation of dosing (juvenile to young adult). Monkeys were pair housed in suspended stainless steel cages, maintained on a 12-h light/dark cycle (temperature 72°C ± 4°C, 30-70% humidity), and fed approximately 240 g of Harlan/Teklad 2050C Certified Global 20% Protein Primate Diet daily. Water was provided ad libitum. Vehicles were administered orally by gavage (dose volume of 5 ml/kg, calculated from most recent body weight) for 95-97 days using an appropriately sized syringe and a no. 14 French catheter. Body weights were measured at least weekly beginning 2 weeks prior to dosing, and a fasted terminal body weight was recorded prior to necropsy. Food consumption was estimated daily by pair beginning 1 week prior to dosing. Monkeys were checked at least once daily for viability and cage observations of each pair were recorded daily. Individual clinical observations were recorded twice daily, at the time of dosing, and 1-3 h postdose.
Ophthalmologic examinations. Ophthalmologic examinations consisted of focal illumination and indirect ophthalmoscopy in a subdued light setting. Examinations were preformed 2 weeks prior to dosing, during weeks 4 and 13 in monkeys, 3 weeks prior to dosing and during weeks 4 and 13 in dogs, 2 weeks prior to dosing and during weeks 4 and 12 in mice, and 2 weeks prior to dosing and during weeks 5 and 11 in rats. Ketamine was used to restrain monkeys during ophthalmologic examinations, and all other species were restrained physically.
Veterinary examinations and electrocardiograms. General veterinary examinations and electrocardiograms (ECGs) were performed once pretest and twice during dosing on the dog (weeks -3/-2, 5, and 12) and monkey (weeks -2, 4, and 13) studies. Animals were examined by a staff veterinarian for abnormalities in appearance, body condition, integument, neuromuscular, or musculoskeletal systems. Body temperature was recorded using a Welch Allyn model 679 or 690 electronic thermometer. Blood pressure (diastolic, systolic, and mean arterial) was also measured in restrained, conscious animals using a Cardell veterinary monitor or a Dinamap vital signs monitor (cuff-type indirect measurement). ECGs were also performed on restrained conscious animals using a Schiller Cardiovit AT-60 electrocardiograph. ECGs were recorded using leads I, II, III, aVR, aVL, aVF, V 1 , V 2 , V 3 , and V 4 for dogs and I, II, III, aVR, aVL, aVF, MV, MV 2 , MV 3 , and V 4 for monkeys.
ECG data analysis consisted of a description of the waveform morphology (for P, QRS, and T waves) and measurements of interval duration (PR, QRS, and QT). QTc interval duration was calculated according to the method of Fridericia (Funck-Brentano and Jaillon, 1993) .
Hematology and serum chemistry evaluations. Blood for hematology and serum chemistry was collected during week 14 for mice, weeks 2 and 13 for rats, 3 weeks prior to dosing and during weeks 3 and 12 in dogs and 2 weeks prior to dosing, and during weeks 5 and 11/12 for monkeys. Total blood volume collected per interval for hematology and serum chemistry was 1 ml from mice, 1.5 ml from rats, and 3 ml from dogs and monkeys. Parameters measured are listed in Table 2 . Hematology analysis was performed using CellDyn 3500 (Abbott Laboratories, Abbott Park, IL) and Sysmex R-3000 (Medical Electronics, Miami, FL) hematology analyzers. Serum chemistry parameters were assessed using a CX5CE/Delta (Beckman Instruments, Brea, CA).
Coagulation assessment. Blood for coagulation assessment was collected at necropsy from rats, 3 weeks prior to dosing and during weeks 3 and 12 in dogs, and 2 weeks prior to dosing and during weeks 5 and 11/12 in monkeys. Prothrombin time and activated partial thromboplastin time were assessed using an STA Compact hemostasis analyzer (Diagnostica Stago, Inc., Parsippany, NJ).
Urinalysis. Freshly voided (4 h) and 24-h urine samples were collected from rats during weeks 2 and 13, 3 weeks prior to dosing and during weeks 3 and 12 from dogs, and 2 weeks prior to dosing and during weeks 5 and 11/12 from monkeys. Urine was collected within 24 h prior to blood collection for hematology and serum chemistry. Parameters examined are listed in Table 3 . Urinalysis parameters from the freshly voided (4 h) samples were evaluated using a CX5CE/Delta (Beckman Instruments), whereas urinalysis parameters from the 24-h samples were analyzed using a Bayer Clintek ATLAS (Bayer Diagnostics, Tarrytown, NY).
Macroscopic and histopathological evaluation. Rats and mice were humanely euthanized by exsanguination under isoflorane anesthesia and dogs and monkeys by exsanguination following sodium pentobarbital-induced anesthesia. Tissues collected are listed in Table 4 , whereas those that were weighed are listed in Table 5 . All tissues were fixed in 10% neutral buffered formalin with the exception of the eyes (3% glutaraldehyde), harderian glands (3% glutaraldehyde), and testes (10% neutral buffered formalin in mice and rats; modified Davidson's fixative in dogs and monkeys). Tissues were then trimmed, embedded in paraffin wax, and sectioned at 4-5 microns. All tissues were stained with hematoxylin and eosin, with the exception of the testes and epididymides of the mouse and rat, which were stained with periodic acidSchiff stain. All tissues from all dose groups were examined by a boardcertified veterinary pathologist. Bone marrow smears were obtained from the sternum (mouse and rat) or rib (dog and monkey) and were evaluated for cytology by a board-certified veterinary clinical pathologist.
Statistics. Descriptive statistics (mean, index of variability, SEM, SD) were calculated for all parameters except ECGs. A student's t-test was used to assess statistical significance of the serum transanimase values in mice and rats. Measured in rat, dog, and monkey studies only.
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RESULTS
The MC MC is one of the most commonly used preclinical vehicles and is the most commonly used vehicle in the testing facility and was therefore considered the ''control'' for comparative purposes in these studies; 20 mg/kg MC (0.4% wt/vol) was well tolerated in all species tested. All clinical observations, body weights, food consumption, clinical pathology, ophthalmologic, histopathology, ECG, and survival parameters evaluated were similar to previous experience in 3-month studies with this vehicle in this facility.
The PS80
In total, 10 mg/kg (0.2% wt/vol) PS80 was well tolerated in mice, rats, dogs, and monkeys. No differences in any parameters were observed between MC and P80. A single male animal in the 3-month dog study experienced loose and/or soft stool on 19 occasions. This was not considered related to P80 treatment because all other animals in this dose group were similar to MC controls.
The PG
In all, 1000 mg/kg (20% wt/vol) PG was well tolerated by mice, rats, dogs, and monkeys. No significant differences in any parameters were observed between MC and PG. One female animal in the 3-month dog study experienced loose and/ or soft stool on 10 occasions. This was not considered related to PG treatment because all other animals in this dose group were similar to MC controls.
Two male animals in the 3-month mouse study had elevated serum alanine aminotransferase (ALT) values at week 13 (48 and 53 IU/ml compared with 19-26 IU/ml for MC controls, see Table 6 ), and one also had an elevated serum aspartate aminotransferase (AST) value at this time point (282 IU/ml compared with 71-84 IU/ml for MC controls). This was not considered related to PG treatment because the other animals in this dose group were similar to MC controls, and spurious elevations in serum transaminase levels such as this are not uncommon in mice in this facility, possibly because of differences in handling (Swaim et al., 1984) . Based on the available literature, the liver is not a sensitive target organ of PG in most species (Anonymous, 1994) . Additionally, the mean ALT value for this dose group was not statistically different from MC, there was no correlating hepatic histopathology, and liver weights were normal, as were alkaline phosphatase (AP) and d-glutamyl transferase (GGT) levels.
The HPbCD
Although HPbCD was generally well tolerated, several vehicle-related findings were observed. In dogs and monkeys, the incidence of loose and/or soft stool was increased in the 1000 mg/kg HPbCD dose groups (Tables 7 and 8 ). The incidence of loose and/or soft stool was also minimally increased in male, but not in female dogs treated with 500 mg/kg HPbCD.
In female rats, treatment with 500 or 1000 mg/kg HPbCD resulted in time-and dose-dependent increases in serum AST and ALT levels (Fig. 1) . After 3 weeks of treatment with 1000 mg/kg HPbCD, serum AST and ALT levels were elevated (þ 38.2% and þ 31.1%, respectively), whereas after 13 weeks of treatment, serum AST and ALT levels were elevated in animals treated with 500 and 1000 mg/kg HPbCD (AST: þ 49.3% and þ 11.5%, ALT: þ 64.8% and þ 195.2%, respectively). In the 1000 mg/kg dose group at week 13, increases in serum AST and ALT levels were significantly higher than those seen at week 2, suggesting a progression of hepatic toxicity in these animals. AP and GGT were unchanged, and male rats were unaffected. Upon microscopic examination, there was no hepatic histopathologic correlate for the elevated transaminase findings, and liver weight and macroscopic appearance were normal. AST and ALT levels in male rats were similar to controls are all time points examined.
In mice, 4/5 male animals in the 1000 mg/kg HPbCD dose group had minimally elevated ALT levels after 13 weeks of treatment, and the mean ALT value for this dose group were statistically different from MC (Table 6 ). The toxicological significance of this finding is uncertain given that serum AST values were normal in these animals, and hepatic weight, macroscopic appearance, and histopathology were similar to controls. All other parameters evaluated, including body weights, food consumption, ophthalmology, histopathology, and ECGs, were similar to historical controls in this facility.
DISCUSSION
Vehicle use in preclinical safety studies varies widely across the pharmaceutical industry (Gad et al., 2006) . In addition to producing solutions or suspensions which are dosable, stable, and bioavailable, it is critical that biological effects produced by vehicles be minimized or at the very least well understood. Unanticipated vehicle-related effects can compromise the integrity of safety studies and result in costly delays in the development of potentially life-saving NCEs. In the present studies, we have completed a battery of oral safety studies using MC, PS80, PG, and HPbCD. The goal of these studies Note. LD HPbCD, low-dose (500 mg/kg) HPbCD; HD HPbCD, high-dose (1000 mg/kg) HPbCD.
a Average incidence of stool findings represent the average total incidence of each finding per animal over the course of the study for each dose group. Note. LD HPbCD, low-dose (500 mg/kg) HPbCD; HD HPbCD, high-dose (1000 mg/kg) HPbCD.
a Average incidence of stool findings represent the average total incidence of each finding per animal over the course of the study for each dose group.
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was to determine their suitability for future use in INDenabling drug safety studies.
MC is used as a direct and indirect food additive (21 CFR 172.874), as well as an inactive ingredient in pharmaceutical products (Rowe, 2009 ). MC has extremely low oral bioavailability (Gorzinski et al., 1986) and is practically nontoxic (reviewed by Burdock, 2007) , with a no observable adverse effect level (NOAEL) in the rat of at least 1020 mg/kg when administered via oral gavage (Obara et al., 1999) . However, the lack of intestinal absorption of MC may lead to a laxative effect at large doses. Dietary administration of MC up to 10% in rats and 6% in dogs for 90 days has also been reported to be without toxicological effects (McCollister et al., 1973) . MC is one of the most commonly used preclinical vehicles and is the most commonly used vehicle in the testing facility and was therefore considered the ''control'' for comparative purposes in these studies. Although toxicological data support the use of MC in g/kg quantities, it is commonly used in the 0.2-0.5% (wt/vol) range as an emulsifying and suspending agent. As expected based on previously published data, in the studies presented herein, no MC-related effects were observed at a dose level of 20 mg/kg (0.4% wt/vol).
PS80 is a widely used nonionic surfactant in cosmetics, food products, and oral, parenteral, and topical pharmaceutical formulations (Rowe, 2009) . It is listed in the United States Food and Drug Administration (USFDA) Inactive Ingredient Database in oral suspensions at concentrations of up to 12.5% and is frequently used in oral preclinical safety studies at concentrations up to 1% (wt/vol). We examined 0.2% PS80 in water, but it is commonly combined with other vehicle excipients, such as MC. PS80 is generally considered nontoxic; however, hypersensitivity reactions have been reported in clinical use (Shelley et al., 1995) and in preclinical studies, hypersensitivity is observed in dogs when administered iv (Eschalier et al., 1988) . The NOAEL for PS80 in rat dietary studies has been established as 2% (approximately 1 g/kg, Elder, 1984) . However, there is a relative paucity of repeat-dose toxicity data in dogs and nonhuman primates for PS80. Our results confirm the appropriateness of 0.2% PS80 for use in safety studies in mice and rats, and establish that this level in an oral formulation is also without significant biological effects in dogs and nonhuman primates over the course of 3 months of treatment.
Iv administration of polysorbate to dogs and other canine species has been associated with an idiosyncratic reaction characterized by a prolonged depressor response (Krantz et al., 1951) . This hypotensive response was caused by a marked release of histamine after iv intake of PS80 in dogs (Elder, 1984; Masini et al., 1985) . Importantly, hypersensitivity (as assessed by clinical signs, ECGs, and clinic pathology) was not observed in any species at this dose level following oral administration.
Like PS80, PG is listed in the USFDA Inactive Ingredient Database as an oral excipient and is a commonly used pharmaceutical excipient (Rowe, 2009) . PG is generally recognized as safe (21 CFR 184.1666) , and the joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives has set the acceptable human intake at 25 mg/ kg/day. PG is commonly used as a solvent in preclinical studies, and the reported NOAEL in the rat is over 2.5 g/kg (Gaunt et al., 1971) . Although PG has a low order of toxicity, it can have an intoxicating effect at high doses (Arulanantham and Genel, 1978) , and repeat-dose toxicity data in the nonhuman primate is not available (Anonymous, 1994) . Our results confirm the appropriateness of 1000 mg/kg PG for use in preclinical safety studies utilizing the rat and dog and establish the NOAEL for this vehicle at 1000 mg/kg in the mouse and nonhuman primate. Although minimally elevated transaminase levels were observed in 2/5 male mice in the study presented herein, all female mice had normal transaminase levels, and no other markers of hepatic toxicity were present or obvious. The minimally elevated transaminase levels were therefore considered incidental, and all other parameters were similar to MC and PS80.
HPbCD is also a commonly used pharmaceutical excipient and is listed in the USFDA Inactive Ingredient Database as an oral excipient at concentrations of up to 40% (Rowe, 2009 ). This is a particularly useful vehicle because of its ''bucket shape'' structure and ability to form inclusion complexes with hydrophobic NCEs. HPbCD is well tolerated in humans and considered nontoxic when administered orally. However, the available toxicity literature was not considered sufficiently robust to support the use of HPbCD in GLP toxicology studies across multiple species. In particular, data are limited in mice and nonhuman primates. In our hands, administration of formulations containing 500 or 1000 mg/kg of HPbCD resulted in vehicle-related toxicities in all species. In dogs and monkeys, the findings were limited to soft and/or loose stool at 1000 mg/kg. Similar findings have been previously reported in dogs and rats (Bellringer et al., 1995; Gould and Scott, 2005) and are likely related to the large load of poorly digestible, osomotically active carbohydrates (Stella and He, 2008) . HPbCD (20%) has been shown to increase gastric emptying time and decrease intestinal transit time in rats (Pestel et al., 2006) ; however, no evidence of altered gastrointestinal function was detected in either rodent species in the current studies. Given the minimal nature of the stool findings in dogs and nonhuman primates, the authors feel they do not necessarily represent an obstacle for use in preclinical toxicity studies.
Previous studies have demonstrated that large doses of HPbCD have a hypocholesterolemic effect in rats (Gar(ciaMediavilla et al., 2003; Levrat et al., 1994; Riottot et al., 1993) . This is because of the ability of HPbCD to form inclusion complexes with cholesterol and inhibit cholesterol absorption. However, under our study conditions, administration of 500 or 1000 mg/kg of HPbCD for 3 months did not affect cholesterol or triglyceride levels in any species tested. Presenting more of a potential liability for a preclinical vehicle were the observed transaminase elevations in rodent species upon administration of oral HPbCD. Our data corroborate previous reports in rats indicating that transaminase levels are elevated in rats following oral administration of HPbCD, albeit at high doses (Bellringer et al., 1995; Garcia-Mediavilla et al., 2003; Gould and Scott, 2005) . Although the transaminase elevations observed were relatively small in magnitude in both species tested, the timeand dose-dependent nature of the serum ALT and AST elevations in female rats suggest progressive hepatic toxicity. ALT is generally considered to be a more liver-specific biomarker than AST. Therefore, the ALT elevations we observed in male mice are noteworthy given the context of the ALT/AST increases seen in female rats. Despite this, there were no hepatic histopathological correlates in either species, and liver weights and AP and GGT levels were within normal ranges for the species tested. Additionally, there was no evidence of skeletal muscle toxicity in either species. Therefore, the nature and toxicological significance of the elevated transaminase levels are unknown. Previous work has demonstrated that higher doses of oral HPbCD can lead to hepatic necrosis (Bellringer et al., 1995; Garcia-Mediavilla et al., 2003; Gould and Scott, 2005) . Interestingly, female mice and male rats failed to show alterations in transaminase levels in our studies. However, regardless of the etiology of these findings, it is the authors' opinion that they limit the usefulness of HPbCD and/or may complicate data interpretation in general repeat-dose preclinical safety studies at concentrations 10% in these species because of the critical role of AST and ALT as biomarkers of NCErelated hepatic and muscle toxicity (Ozer et al., 2007) . Given the observations reported in rodent species, it is possible that HPbCD may mask such toxicities when used at the concentrations studied.
Interestingly, iv administration of HPbCD leads to an entirely different sequelae of toxicities. The most prominent toxicity observed with iv administration of HPbCD is vacuolization of the renal proximal tubules and urinary bladder epithelium (Frank et al., 1976; Frijlink et al., 1991; Gould and Scott, 2005) . With prolonged HPbCD exposure at high doses, the damage to the proximal tubules can become toxicologically (or clinically) significant. The mechanism for these effects is believed to be related to the concentration of HPbCD in kidney tissues secondary to renal excretion, and subsequent local osmotic imbalance (Frank et al., 1976) . The fact that transaminase elevations are observed at oral doses as low as 500 mg/kg in this study, but not observed at iv doses of 100 mg/kg at which renal toxicity is observed (Coussement et al., 1990 ) is unusual considering the low oral bioavailability (< 2% in the rat) of HPbCD (Gerloczy et al., 1990; Monbaliu et al., 1990) . Clearly systemic exposure to HPbCD is considerably higher when 100 mg/kg of HPbCD is administered iv, as compared with a 500 mg/kg oral dose. This suggests that the transaminase elevations observed following oral exposure may not be directly related to systemic HPbCD exposure. Alternatively, the transaminase elevations may be a result of first pass accumulation in the liver or metabolism of HPbCD in the gastrointestinal tract or liver.
Another potential confounding issue with the use of HPbCD in preclinical safety studies comes from reports of carcinogenic activity of HPbCD in rats. Although some studies have reported no carcinogenic potential (Toyoda et al., 1997; Waner et al., 1995) , other reports indicate there is an increased incidence of pancreatic exocrine tumors in rats (Gould and Scott, 2005; Irie and Uekama, 1997) . The mechanism underlying this effect is believed to involve HPbCD-dependent upregulation of cholecystokinin, though the details supporting this mechanism are unclear at this time. Although it is unknown if this mechanism is relevant to human risk, the interpretation of data from chronic drug safety studies utilizing HPbCD in rats may be more challenging because of these effects.
Collectively, the above data represent significant complicating factors with respect to the preclinical use of HPbCD at concentrations 10%; however, it remains an important option because of its superior solubilizing characteristics. HPbCD is still ideal for single-dose or short-repeat dose studies or large animal studies in which soft or loose stool may be considered an acceptable or tolerated observation. Vehicles containing HPbCD may also be acceptable in studies in which hepatotoxicity is not evaluated or studies in which HPbCDrelated effects (described above) can be easily separated from NCE-related effects. Although our work has not established a no-effect level for the toxicities described, lower doses of HPbCD, if physiochemically useful, may also be explored.
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The data presented in this report support the use of MC, PS80 and PG in preclinical safety studies. However, it is recommended that HPbCD be used with caution at the doses described herein because of the potential for confounding vehicle-related toxicity.
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